• Prabha Thangavelu Department of Pharmaceutical Chemistry, Nandha College of Pharmacy, Koorapalayam Pirivu, Pitchandam Palayam Post, Erode 638052, Tamil Nadu, India
  • Selvinthanuja Cellappa Department of Pharmaceutical Chemistry, Nandha College of Pharmacy, Koorapalayam Pirivu, Pitchandam Palayam Post, Erode 638052, Tamil Nadu, India
  • Sivakumar Thangavel Department of Pharmaceutical Chemistry, Nandha College of Pharmacy, Koorapalayam Pirivu, Pitchandam Palayam Post, Erode 638052, Tamil Nadu, India



Formazans, Schiff base, Enoyl-ACP Reductase, Docking, MOE


Objective: To synthesize, evaluate and performing the docking studies of novel formazan derivatives as enoyl-ACP reductase inhibitors.

Materials: In the present investigation, a series of formazans (Ia-d) were synthesized by stirring aryl diazonium salts solution with Schiff's base at 0-5ËšC for 2 h. The intermediate azomethine (Schiff base) itself was synthesized by condensation of para aminobenzoic acid with dimethylamino benzaldehyde in presence of a glacial acetic acid as a catalyst. The antimicrobial activity was done for these synthesized compounds by cup plate method. Moreover, the antimicrobial activity was further confirmed by its molecular docking approach study by using Molecular Operating Environment (MOE) 2009.10 software.

Results: In the present study all the synthesized compounds (Ia-Id) showed the enhanced zone of inhibition against S. aureus, B. subtilis, E. coli and S. typhi (5±0.12 to 12±0.45) whereas, the antifungal activity against A. niger and C. albicans were showed the zone of inhibition in the range of 9±0.51 to 12±0.43 when compared to that of the standard drug.

Further the docking study reveals that, only three of the formazan compounds under observation (Ia, Ib and Ic) have higher binding affinity with the receptors enzymes enoyl-ACP reductase, which is in the narrow range of binding energy for the protein PDB: 1C14 is-24.4598 to-23.9377 kcal/mol, which shows the further confirmation of these formazan compounds as better microbial inhibitor.

Conclusion: Therefore our present report shows that formazans could be the potential drug candidate that inhibits the microbial activity by interacting and inhibiting the enoyl-ACP reductase enzyme which is confirmed by its both in vitro antimicrobial study and as well as from its docking study.


Download data is not yet available.


Sunil KS, Usha C. Computational approaches for the prediction of antimicrobial potential peptides from ocimum tenuiflorum. Asian J Pharm Clin Res 2018;11:398-401.

Subramanian A, Kannan N, Mani P. Antimicrobial activity and phytochemical screening of the leaf extracts of Eucalyptus Globulus. Int J Curr Pharm Res 2017;9:85-9.

Şenöz H. The chemistry of formazans and tetrazolium salts, hacettepe. J Biol Chem 2012;40:293-301.

Anand B, Venkatesan P, Matheswaran P. Influence of formazan derivatives on corrosion inhibition of mild steel in the hydrochloric acid medium. J Chem 2009;6:S438-44.

Chavan SB, Zangade SB, Archana, VIbhute Y, Vibhute YB. Synthesis and evaluation of antimicrobial activity of some new Schiff bases and formazans. J Chem Pharm Res 2012;3:262-9.

Tiwari MM, Agarwal M, Sexena VK, Bajpai SK, Joshi MM. Synthesis and antiviral activity of some new formazans. Indian J Pharm Sci 1995;57:113-6.

Mukerjee DD, Shukla SK, Chowdhary BL. Synthesis of some new formazans as potential antiviral agents. Arch Pharm (Weinheim) 1981;314:991-4.

Pandey VK, Negi HS. Synthesis of 1-(2’ aryl-4’-oxo-3H-quinazoloyl)-3-aryl-5-phenyl formazan as potential antiviral agents. Indian Drugs 1990;36:37-40.

Nadendla RR, Mukkanti K, Rao GS, Babu AN. Microwave synthesis of some new quinazolinoneformazans for their antimicrobial and anthelmintic activities. Curr Trends Biotech Pharm 2010;4:545–50.

Rajput SS. Synthesis, characterization and antimicrobial activity of 1-isonicotinoyl-3-(4-methoxy phenyl)-5-(substituted phenyl) formazans. Int J Adv Pharm Biol Chem 2013;2:376–9.

Desai RM, Desai JM, Shah VH. Synthesis and antimicrobial profiles of 1,3,4-oxadiazoles, sulphonamides, 5-imidazolinones, azomethines, 4-thiazolidinones, 2-azetidinones, formazans and tetrazolium chlorides. Indian J Heterocycl Chem 1999;8:329–34.

Revanasiddappa BC, Subrahmanyam EVS. Synthesis and biological studies of some novel formazans. Oriental J Chem 2010;26:243–6.

Lakshmi N, Haritha V, Sreeram V, Rajalakshmi D, Sindhura N, Visagaperumal D. Synthesis and their possible biological activities of few formazans of 3-amino-2-sulphanyl-2,3,4,5,6,7,8-hexahydrobenzothieno-[2,3-d]pyrimidin-4(1H)-one. Rasayan J Chem 2009;2:71–4.

Raval JP, Patel PR, Patel NH, Patel PS, Bhatt VD, Patel KN. Synthesis, Characterization and in vitro antibacterial activity of novel 3-(4-methoxyphenyl)-1-isonicotinoyl-5-(substituted phenyl)-formazans. Int J Chem Tech Res 2009;1:610–5.

Desai JM, Shah VH. Synthesis and antimicrobial profile of 5-imidazo-lones, sulphonamides, azomethines, 2-azetidinones and formazans derived from 2-amino-3-cyano-5-(5′-chloro-3′-methyl-1′-phenylpyrazol-4′-yl-vinyl)-7,7′-dimethyl-6,7-dihydrobenzothiophenes. Indian J Chem 2003;42:631–5.

Kidwai M, Negi N, Gupta SD. Synthesis and antifertility activity of 1,5-diaryl-3-(3’-indolyl)formazans. Chem Pharm Bull 1994;42:2363-4.

Babu AN, Nadendla RR. Synthesis of some new quinazolinoneformazans as anti-inflammatory and anthelmintic agents. J Pharm Res 2011;4:983–5.

Singh N, Bhati SK, Kumar A. Thiazolyl/oxazolyl formazanylindoles as potent anti-inflammatory agents. Eu J Med Chem 2008;43:2597–609.

Kalsi R, Pande K, Bhalla TN, Parmar SS, Barthwal JP. Novel formazans as potent anti-inflammatory and analgesic agents. Pharmacology 1988;37:218–24.

Kaisi R, Pande K, Bhalla TN, Barthwal JP, Gupta GP, Parmar SS. Anti-inflammatory activity of quinazolinoformazans. J Pharm Sci 1990;79:317–20.

Raval JP, Patel P, Pradip S, Patel PS. In vitro antitubercular activity of novel 3-(4-methoxyphenyl)-1-isonicotinoyl-5-(substituted phenyl) formazans. Int J Pharm Tech Res 2009;1:1548–53.

Tandel DC, Desai CM, Patel D, Naik B, Matjad S. Synthesis of quinolinyldiarylformazans as anti-tubercular/antibacterial agents. Oriental J Chem 2001;17:529–30.

Srivastava A, Kumar AV. Synthesis of newer formazan potential anticonvulsant agents. Indian J Pharm Sci 2001;65:358–62.

Archana, Srivastava VK, Kumar A. Synthesis of newer indolylthiadiazoles and their thiazolidinones and formazans as potential anticonvulsant agents. Indian J Pharm Sci 2003;65:358-62.

Khanna R, Palit G, Srivastava VK, Shanker K. Newer heterocycles of phenothiazine and their antiparkinsonian activity. Indian J Chem 1990;29B:556–60.

Kumar P, Nath C, Shanker K. Newer dopamine quinazolones as anti parkinsonian agents. Pharmazie 1985;40:267–8.

Bhardwaj SD, Jolly VS. Synthesis, anti-HIV and anticancer activities of some new formazans. Asian J Chem 1997;9:48–51.

Bhardwaj SD. Synthesis, anti-cancer and anti-HIV activities of some new formazans. Asian J Chem 1998;10:39–42.

Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Human Retrovirus 2002;18:989-97.

Yaglıoglu AS, Senoz H. The anti-proliferative effects of substituents in formazan derivatives against HeLa and C6 cell line. J Biol Chem 2013;41:371–8.

Adler RA, Naumann SA, Mansouri A, Krieg Jr RJ, Latta K, Sanders KM. Anti-proliferative effects of deflazacort on NB2 cells as quantitated by formazan production. Life Sci 1994;55:1823–31.

Haider A Mahdi, Karim S Abbas, Hiba M Dagher. Synthesis, characterization and anti-hyperglycemic activity of some novel formazans derivatives. Chem Mat Res 2015;7:72-80.

Knowles DJ, New strategies for antibacterial drug design. Trends Microbiol 1997;5:379-83.

Harris CR, Thorarensen A. Advances in the discovery of novel antibacterial agents. Curr Med Chem 2004;11:2213-43.

Chopra I, Hodgson J, Metcalf B, Poste G. New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective. JAMA 1996;275:401-3.

Kumar A, Siddiqi MI. Recent progress in the development of Mycobacterium tuberculosis enoyl acyl carrier protein reductase inhibitors as anti-tubercular agents. Biobytes 2009;4:2.

Halgren TA, Nachbar RB. Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comp Chem 1996;17:587-615.



How to Cite

Thangavelu, P., S. Cellappa, and S. Thangavel. “SYNTHESIS, EVALUATION AND DOCKING STUDIES OF NOVEL FORMAZAN DERIVATIVES AS AN ENOYL-ACP REDUCTASE INHIBITORS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 10, no. 8, Aug. 2018, pp. 56-61, doi:10.22159/ijpps.2018v10i8.26819.



Original Article(s)